Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription pharmaceutical products. Its portfolio of brands includes Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection, for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation; Sancuso (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
äŒæ¥ã³ãŒãCPIX
äŒç€ŸåCumberland Pharmaceuticals Inc
äžå Žæ¥Aug 11, 2009
æé«çµå¶è²¬ä»»è
ãCEOãKazimi (A. J)
åŸæ¥å¡æ°91
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 11
æ¬ç€Ÿæåšå°1600 West End Avenue, Suite 1300
éœåžNASHVILLE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·37203
é»è©±çªå·18774842700
ãŠã§ããµã€ãhttps://www.cumberlandpharma.com/
äŒæ¥ã³ãŒãCPIX
äžå Žæ¥Aug 11, 2009
æé«çµå¶è²¬ä»»è
ãCEOãKazimi (A. J)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã